Nordic Life Science 1
BUSINE S S D E A L FINNISH GINOLIS IS FOCUSING ON
DIAGNOSTICS AUTOMATION AND ADVANCED ROBOTICS SOLUTIONS FOR MEDICAL AND DIAGNOSTIC INDUSTRIES. F orty percent of the purchase price will be paid in newly issued shares of series B in Cellink and the remaining purchase price in cash. “Many of the tools offered by Ginolis will ensure higher quality bioprinting experiments and results, faster throughput of printed tissues, and more reliable and reproducible data. In addition, it is also possible for the Group to further capitalize on the current rapid growth in the application area of PoC-tests where Ginolis is currently manufacturing COVID-19 tests in the US and Europe,” says Erik Gatenholm, CEO, Cellink. Erik Gatenholm, CEO, Cellink